Target Price | $8.67 |
Price | $0.94 |
Potential |
822.18%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Ventyx Biosciences 2026 .
The average Ventyx Biosciences target price is $8.67.
This is
822.18%
register free of charge
$15.00
1,496.08%
register free of charge
$1.00
6.41%
register free of charge
|
|
A rating was issued by 8 analysts: 6 Analysts recommend Ventyx Biosciences to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Ventyx Biosciences stock has an average upside potential 2026 of
822.18%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.97 | -2.05 |
40.30% | 4.06% | |
P/E | negative |
3 Analysts have issued a Ventyx Biosciences forecast for earnings per share. The average Ventyx Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Ventyx Biosciences...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 15 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 23 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 08 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 15 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 23 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.